🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this investigator-initiated, multicenter phase II trial is t...
Status
Recruiting
Location
Aalborg University Hospital
Start Date
2023-02-01
Trial ID
NCT05732389
Treatments Being Tested
This is a randomized, open-label, multi-center Phase III study to determine...
Status
Active Not Recruiting
Location
Research Site
Start Date
2017-01-02
Trial ID
NCT03003962
To assess safety and tolerability, describe the dose-limiting toxicities, a...
Status
Completed
Location
Research Site
Start Date
2018-12-20
Trial ID
NCT03811652
Treatments Being Tested
This phase II trial investigates the effect of NBTXR3, radiation therapy, a...
Status
Terminated
Location
M D Anderson Cancer Center
Start Date
2021-04-07
Trial ID
NCT04862455
This study is being done to look at the combination of the drugs atezolizum...
Status
Withdrawn
Location
Princess Margaret Cancer Centre
Start Date
2021-07-16
Trial ID
NCT04510584
Treatments Being Tested
Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibito...
Status
Unknown
Location
CHU d'ANGERS
Start Date
2019-04-09
Trial ID
NCT03865511
Treatments Being Tested
This phase II study will explore the effect of 2 monoclonal antibodies, tir...
Status
Recruiting
Location
Border Medical Oncology Research Unit
Start Date
2023-12-15
Trial ID
NCT06003621
Treatments Being Tested
The purpose of this observational study is to collect and evaluate real-wor...
Status
Recruiting
Location
Klinikverbund Allgaeu
Start Date
2023-11-30
Trial ID
NCT06169956
Treatments Being Tested
This is a multicenter, open-label, Phase 1/2 master protocol evaluating aut...
Status
Recruiting
Location
Peking University Shenzhen Hospital
Start Date
2026-03-02
Trial ID
NCT07523529
This phase I/II clinical trial evaluates the safety, efficacy, and prognost...
Status
Enrolling By Invitation
Location
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
Start Date
2024-03-30
Trial ID
NCT06690216